IMDX
$4.53
Insight Molecular Diagnostics Inc.
Intraday
Recent News
How Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Capital And GraftAssureDx Milestones
The updated analyst narrative on Insight Molecular Diagnostics now centers on a fresh price target of $12 per share, while the internal fair value estimate remains at $8.33. Analysts linking this move to the recent $26m capital raise and the expected FDA submission for GraftAssureDx see funding visibility and a clearer regulatory path as key drivers of the higher target, with others still cautious about execution and approval risk. As you read on, you will see how these competing views shape...
How Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And GraftAssureDx Catalyst
Insight Molecular Diagnostics is back in focus after analysts updated their price target, with some now pointing to US$12 alongside a refreshed fair value estimate of US$8.33, previously US$7.00. That shift is being linked to views on the recent US$26m offering, funding visibility around upcoming milestones, and expectations for the planned FDA submission for GraftAssureDx, even as others flag the associated risks. As you read on, you will see how this evolving narrative might shape sentiment...
Insight ‘congratulated’ STAR working group on organ health testing paper
Insight Molecular Diagnostics (IMDX) “congratulated” the STAR working group on its position paper in the American Journal of Transplantation in recognizing the need for decentralized organ health testing in the global transplant community. “We completely agree with the working group’s conclusion. It’s high time that we give transplant centers the tools that they need to build guidelines and manage patients themselves,” iMDx CEO Josh Riggs said. “Such a full-throated call for access to test kits
Insiders Rewarded With US$5.2m Addition To Investment As Insight Molecular Diagnostics Stock Hits US$183m
Last week, Insight Molecular Diagnostics Inc. ( NASDAQ:IMDX ) insiders, who had purchased shares in the previous 12...
We're Keeping An Eye On Insight Molecular Diagnostics' (NASDAQ:IMDX) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. Indeed, Insight Molecular Diagnostics...